Catalyst Pharmaceuticals (CPRX) Upgraded at BidaskClub

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

A number of other research firms have also recently weighed in on CPRX. Cantor Fitzgerald set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 8th. HC Wainwright reaffirmed a “buy” rating on shares of Catalyst Pharmaceuticals in a report on Friday, December 14th. Oppenheimer set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 29th. Piper Jaffray Companies lifted their target price on shares of Catalyst Pharmaceuticals from $5.00 to $7.50 and gave the company an “overweight” rating in a report on Thursday, December 13th. Finally, Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Catalyst Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.35.

CPRX stock opened at $2.69 on Thursday. Catalyst Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $4.05. The company has a market cap of $273.29 million, a price-to-earnings ratio of -12.81 and a beta of 2.31.

In other news, insider Patrick J. Mcenany acquired 20,000 shares of the stock in a transaction that occurred on Wednesday, December 19th. The shares were purchased at an average cost of $2.24 per share, for a total transaction of $44,800.00. Following the transaction, the insider now directly owns 4,737,693 shares in the company, valued at approximately $10,612,432.32. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald A. Denkhaus acquired 25,000 shares of the stock in a transaction that occurred on Thursday, December 27th. The stock was purchased at an average price of $1.91 per share, for a total transaction of $47,750.00. Following the completion of the transaction, the director now owns 225,000 shares in the company, valued at $429,750. The disclosure for this purchase can be found here. Insiders bought a total of 65,000 shares of company stock worth $142,550 over the last ninety days. Corporate insiders own 9.30% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in Catalyst Pharmaceuticals by 11.5% in the 4th quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after buying an additional 719,093 shares during the last quarter. Vanguard Group Inc. grew its position in Catalyst Pharmaceuticals by 4.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,458,151 shares of the biopharmaceutical company’s stock valued at $16,852,000 after buying an additional 185,017 shares during the last quarter. Vanguard Group Inc grew its position in Catalyst Pharmaceuticals by 4.3% in the 3rd quarter. Vanguard Group Inc now owns 4,458,151 shares of the biopharmaceutical company’s stock valued at $16,852,000 after buying an additional 185,017 shares during the last quarter. Sofinnova Ventures Inc grew its position in Catalyst Pharmaceuticals by 6.9% in the 3rd quarter. Sofinnova Ventures Inc now owns 1,549,552 shares of the biopharmaceutical company’s stock valued at $5,858,000 after buying an additional 99,595 shares during the last quarter. Finally, Northern Trust Corp grew its position in Catalyst Pharmaceuticals by 9.7% in the 2nd quarter. Northern Trust Corp now owns 1,107,944 shares of the biopharmaceutical company’s stock valued at $3,458,000 after buying an additional 97,997 shares during the last quarter. Hedge funds and other institutional investors own 49.83% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Recommended Story: Preferred Stock

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply